pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2010-4-88-95pulmo-1676Research ArticleСтатьиСовременные подходы к профилактике пневмококковой
инфекцииКозловР. С.roman@antibiotic.ruАндрееваИ. В.andreeva@antibiotic.ruМартиновичА. А.lex.martinovich@antibiotic.ruНИИ антимикробной химиотерапии Государственного образовательного учреждения высшего профессионального образования "Смоленская государственная
медицинская академия Федерального агентства по здравоохранению и социальному развитию"Russian Federation201028082010048895Copyright © Козлов Р.С., Андреева И.В., Мартинович А.А., 20102010Козлов Р.С., Андреева И.В., Мартинович А.А.Козлов Р.С., Андреева И.В., Мартинович А.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1676пневмококковая инфекцияпневмококковая вакцинапрофилактикаанализ "стоимость-эффективность"нежелательные реакциирезистентные штаммынекапсульные антигеныReferencesWright A.E., Morgan W.P., Cantab M.B. et al. Observation on prophylactic inoculations against pneumococcus infec tion, and on the results which have been achieved by it. Lancet 1914; 1: 87-95.Wright A.E., Morgan W.P., Cantab M.B. et al. Observation on prophylactic inoculations against pneumococcus infec tion, and on the results which have been achieved by it. Lancet 1914; 1: 87-95.Heidelberg M., Avery O.T. The soluble specific substance of pneumococcus. J. Exp. Med. 1923; 38: 73-79.Heidelberg M., Avery O.T. The soluble specific substance of pneumococcus. J. Exp. Med. 1923; 38: 73-79.Schiemann O., Casper W. Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z. Hyg. Infektionskr. 1927; 108: 220-257.Schiemann O., Casper W. Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z. Hyg. Infektionskr. 1927; 108: 220-257.MacLeod C.M., Hodges R.G., Heidelberg M. et al. Preven tion of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 1945; 82: 445-465.MacLeod C.M., Hodges R.G., Heidelberg M. et al. Preven tion of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 1945; 82: 445-465.Austrian R., Gold J. Pneumococcal bacteremia with a special reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 1964; 60: 759-776.Austrian R., Gold J. Pneumococcal bacteremia with a special reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 1964; 60: 759-776.Austrian R., Douglas R.M., Schiffman G. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 1976; 89: 184-189.Austrian R., Douglas R.M., Schiffman G. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 1976; 89: 184-189.Smit P., Oberholzer D., Hayden-Smith S. et al. Protective efficacy of pneumococcal polysaccharide vaccines. J.A.M.A. 1977; 238: 2613-2616.Smit P., Oberholzer D., Hayden-Smith S. et al. Protective efficacy of pneumococcal polysaccharide vaccines. J.A.M.A. 1977; 238: 2613-2616.Advisory Committee on Immunization Practices. Preven tion of pneumococcal diseases: recommendations of the advisory committee on immunization practices. Mortal. Morbid. Wkly Rep. 1997; 46: 1-24.Advisory Committee on Immunization Practices. Preven tion of pneumococcal diseases: recommendations of the advisory committee on immunization practices. Mortal. Morbid. Wkly Rep. 1997; 46: 1-24.Butler J.C., Breiman R.F., Campbell J.F. et al. Polysaccha ride pneumococcal vaccine efficacy: an evaluation of cur rent recommendations. J.A.M.A. 1993; 270: 1826-1831.Butler J.C., Breiman R.F., Campbell J.F. et al. Polysaccha ride pneumococcal vaccine efficacy: an evaluation of cur rent recommendations. J.A.M.A. 1993; 270: 1826-1831.Preventing pneumococcal bacteremia at patients at risk. Results of a matched case-control study. Arch. Intern. Med. 1995; 155: 2336-2340.Preventing pneumococcal bacteremia at patients at risk. Results of a matched case-control study. Arch. Intern. Med. 1995; 155: 2336-2340.Sims R.V., Steinmann W.C., McConville J.H. et al. The clin ical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 1988; 108: 653-657.Sims R.V., Steinmann W.C., McConville J.H. et al. The clin ical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 1988; 108: 653-657.Shapiro E.D., Berg A.T., Austrian R. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 1991; 325: 1453-1460.Shapiro E.D., Berg A.T., Austrian R. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 1991; 325: 1453-1460.Jackson L.A., Neuzil K.M., Yu O. et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 2003; 348: 1747-1755.Jackson L.A., Neuzil K.M., Yu O. et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 2003; 348: 1747-1755.Forrester H.L., Jahningen D.W., LaForce F.M. Inefficacy of pneumococcal vaccine in a high-risk population. Am. J. Med. 1987; 83: 425-430.Forrester H.L., Jahningen D.W., LaForce F.M. Inefficacy of pneumococcal vaccine in a high-risk population. Am. J. Med. 1987; 83: 425-430.Johnstone J., Marrie T.J., Eurich D.T. et al. Effect of pneu mococcal vaccination in hospitalized adults with communi tyacquired pneumonia. Arch. Intern. Med. 2007; 167 (18): 1938-1943.Johnstone J., Marrie T.J., Eurich D.T. et al. Effect of pneu mococcal vaccination in hospitalized adults with communi tyacquired pneumonia. Arch. Intern. Med. 2007; 167 (18): 1938-1943.Sisk J.E., Moskowitz A.J., Whang W. et al. Cost!effectiveness of vaccination against pneumococcal bacteremia among elderly people. J.A.M.A. 1997; 278: 1333-1339.Sisk J.E., Moskowitz A.J., Whang W. et al. Cost!effectiveness of vaccination against pneumococcal bacteremia among elderly people. J.A.M.A. 1997; 278: 1333-1339.Ogilvie I., Khoury A.E., Cui Y. et al Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a sys tematic review of conclusions and assumptions. Vaccine 2009; 27 (36): 4891-4904.Ogilvie I., Khoury A.E., Cui Y. et al Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a sys tematic review of conclusions and assumptions. Vaccine 2009; 27 (36): 4891-4904.Fedson D.S., Musher D.M., Eskola J. Pneumococcal vaccine. In: Plotkin S.A., Orenstein W.A., Vaccines 3rd ed. Philadelphia: W.B. Saunders; 1999. 553-607.Fedson D.S., Musher D.M., Eskola J. Pneumococcal vaccine. In: Plotkin S.A., Orenstein W.A., Vaccines 3rd ed. Philadelphia: W.B. Saunders; 1999. 553-607.Fine M.J., Smith M.A., Carson C.A. et al. Efficacy of pneumococcal vaccination in adults: a meta!analysis of random ized controlled trials. Arch. Intern. Med. 1994; 154: 2666-2677.Fine M.J., Smith M.A., Carson C.A. et al. Efficacy of pneumococcal vaccination in adults: a meta!analysis of random ized controlled trials. Arch. Intern. Med. 1994; 154: 2666-2677.Jackson L.A., Benson P., Sneller V.1P. et al. Safety of revac cination with pneumococcal polysaccharide vaccine. J.A.M.A. 1999; 281: 243-248.Jackson L.A., Benson P., Sneller V.1P. et al. Safety of revac cination with pneumococcal polysaccharide vaccine. J.A.M.A. 1999; 281: 243-248.Sankilampi U., Honkanen P.O., Bloigu A. et al. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in patients in the elderly. J. Infect. Dis. 1997; 176: 1100-1104.Sankilampi U., Honkanen P.O., Bloigu A. et al. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in patients in the elderly. J. Infect. Dis. 1997; 176: 1100-1104.Brichacek B., Swindells S., Janoff E.N. et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 1996; 174: 1191-1199.Brichacek B., Swindells S., Janoff E.N. et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 1996; 174: 1191-1199.Katzenstein T.L., Gerstoft J., Nielsen H. Assessments of plas ma HIV RNA and CD4 cell counts after combined Pneumovax® and tetanus toxoid vaccination. Scand. J. Infect. Dis. 1996; 28: 239-241.Katzenstein T.L., Gerstoft J., Nielsen H. Assessments of plas ma HIV RNA and CD4 cell counts after combined Pneumovax® and tetanus toxoid vaccination. Scand. J. Infect. Dis. 1996; 28: 239-241.O'Dempsey T.J.D., McArdle T., Ceesay S.J. et al. Immunization with a pneumococcal capsular polysaccharide vac cine during pregnancy. Vaccine 1996; 14: 963-970.O'Dempsey T.J.D., McArdle T., Ceesay S.J. et al. Immunization with a pneumococcal capsular polysaccharide vac cine during pregnancy. Vaccine 1996; 14: 963-970.Nuorti J.P., Butler J.C., Crutcher J.M. et al. An outbreak of pneumonia and bacteremia due to multidrug-resistant Streptococcus pneumoniae among unvaccinated nursing home residents. N. Engl. J. Med. 1998; 338: 1861-1868.Nuorti J.P., Butler J.C., Crutcher J.M. et al. An outbreak of pneumonia and bacteremia due to multidrug-resistant Streptococcus pneumoniae among unvaccinated nursing home residents. N. Engl. J. Med. 1998; 338: 1861-1868.Centers for Disease Control and Prevention. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic!care facilities - Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996. Mortal. Morbid. Wkly Rep. 1997; 46: 60-62.Centers for Disease Control and Prevention. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic!care facilities - Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996. Mortal. Morbid. Wkly Rep. 1997; 46: 60-62.Fiore A.E., Iverson C., Messmer T. et al. Outbreak of pneumonia in a long!term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J. Am. Geriatr. Soc. 1998; 46: 1112-1117.Fiore A.E., Iverson C., Messmer T. et al. Outbreak of pneumonia in a long!term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J. Am. Geriatr. Soc. 1998; 46: 1112-1117.Rodriguez-Barradas M.C., Tharapel R.A., Groover J.E. et al. Colonization by Streptococcus pneumoniae among human immunodeficiency virus!infected adults: prevalence of antibiotic resistance, impact of immunization, and charac terization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J. Infect. Dis. 1997; 175: 590-597.Rodriguez-Barradas M.C., Tharapel R.A., Groover J.E. et al. Colonization by Streptococcus pneumoniae among human immunodeficiency virus!infected adults: prevalence of antibiotic resistance, impact of immunization, and charac terization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J. Infect. Dis. 1997; 175: 590-597.USPHS / IDSA Prevention of Opportunistic Infections Working Group. Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 127: 922-946.USPHS / IDSA Prevention of Opportunistic Infections Working Group. Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 127: 922-946.Rodriguez-Barradas M.C., Musher D.M., Kahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vac!cine. J. Infect. Dis. 1992; 165: 553-556.Rodriguez-Barradas M.C., Musher D.M., Kahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vac!cine. J. Infect. Dis. 1992; 165: 553-556.Target Product Profile and Technical Requirements. Pre tender Meeting Pneumococcal Vaccines under the AMC, UNICEF Supply Division, Copenhagen, 26 Aug. 2009. Copenhagen; 2009.Target Product Profile and Technical Requirements. Pre tender Meeting Pneumococcal Vaccines under the AMC, UNICEF Supply Division, Copenhagen, 26 Aug. 2009. Copenhagen; 2009.GAVI Alliance. Pneumococcal Vaccines: Suppliers, pipelines, and availability: 4th Annual network conference, 9-10 November 2006.GAVI Alliance. Pneumococcal Vaccines: Suppliers, pipelines, and availability: 4th Annual network conference, 9-10 November 2006.Black S., Shinefeld H., Fireman B. et al. Efficacy, safety and immunogenecity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Group. Pediatr. Infect. Dis. J. 2000; 19: 187-195.Black S., Shinefeld H., Fireman B. et al. Efficacy, safety and immunogenecity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Group. Pediatr. Infect. Dis. J. 2000; 19: 187-195.Centers for Disease Control and Prevention (CDC). Inva sive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. Mortal. Morbid. Wkly Rep. 2008; 57 (6): 144-148.Centers for Disease Control and Prevention (CDC). Inva sive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. Mortal. Morbid. Wkly Rep. 2008; 57 (6): 144-148.Kyaw M.H., Lynfield R., Schaffner W. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug resistant Streptococcus pneumoniae. N. Engl. J. Med. 2006; 354 (14): 1455-1463.Kyaw M.H., Lynfield R., Schaffner W. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug resistant Streptococcus pneumoniae. N. Engl. J. Med. 2006; 354 (14): 1455-1463.Grivea I.N., Panagiotou M., Tsantouli A.G. et al. Impact of heptavalent pneumococcal conjugate vaccine on nasopha ryngeal carriage of penicillin!resistant Streptococcus pneu moniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 2008; 27 (6): 519-525.Grivea I.N., Panagiotou M., Tsantouli A.G. et al. Impact of heptavalent pneumococcal conjugate vaccine on nasopha ryngeal carriage of penicillin!resistant Streptococcus pneu moniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 2008; 27 (6): 519-525.Eskola J., Kilpi T., Palmu A. et al. Efficacy of a pneumococ cal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001; 344 (6): 403-409.Eskola J., Kilpi T., Palmu A. et al. Efficacy of a pneumococ cal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001; 344 (6): 403-409.Wysocki J., Galaj A., Omeсaca F. et al. Data presented at ISPPD 2008. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP, PneumoADIP Report, November 2008.Wysocki J., Galaj A., Omeсaca F. et al. Data presented at ISPPD 2008. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP, PneumoADIP Report, November 2008.Hausdorff W.P. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007; 25 (13): 2406-2412.Hausdorff W.P. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007; 25 (13): 2406-2412.Pneumococcal Regional Serotype Distribution for Pneumo coccal AMC TPP, PneumoADIP Report, November 2008. Available at: www.vaccineamc.org/files/TTP_Codebook.pdfPneumococcal Regional Serotype Distribution for Pneumo coccal AMC TPP, PneumoADIP Report, November 2008. Available at: www.vaccineamc.org/files/TTP_Codebook.pdfPrymula R., Peeters P., Chrobok V. et al. Pneumococcal cap sular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367 (9512): 740-748.Prymula R., Peeters P., Chrobok V. et al. Pneumococcal cap sular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367 (9512): 740-748.Prevnar®. Pneumococcal 7!valent Conjugate Vaccine (Diphtheria CRM197 Protein). Product monograph. Manufactured by: Wyeth Pharmaceuticals. Available from: http://www.wyeth.ca/en/products/Product%20Monograph s%20PDFs/Prevnar_PM_Dec_22_2008_sub_Jan_8_2009. pdfPrevnar®. Pneumococcal 7!valent Conjugate Vaccine (Diphtheria CRM197 Protein). Product monograph. Manufactured by: Wyeth Pharmaceuticals. Available from: http://www.wyeth.ca/en/products/Product%20Monograph s%20PDFs/Prevnar_PM_Dec_22_2008_sub_Jan_8_2009. pdfSynflorix®. Pneumococcal polysaccharide conjugate vaccine, 10-valent adsorbed. Approved Product Information. GlaxoSmithKline Australia Pty Ltd. Available from: http://www.gsk.com.au/resources.ashx/vaccineproductschild1 dataproinfo/151/FileName/F95603879DCA33D25B69CF2D 7FE45D0D/PI_Synflorix.pdfSynflorix®. Pneumococcal polysaccharide conjugate vaccine, 10-valent adsorbed. Approved Product Information. GlaxoSmithKline Australia Pty Ltd. Available from: http://www.gsk.com.au/resources.ashx/vaccineproductschild1 dataproinfo/151/FileName/F95603879DCA33D25B69CF2D 7FE45D0D/PI_Synflorix.pdfRennels M.B., Edwards K.M., Keyserling H.L. et al. Safety and immunogenicity of heptavalent pneumococcal conjugated to CRM197 in United States infants. Pediatrics 1998; 101 (4, Pt 1): 604-611.Rennels M.B., Edwards K.M., Keyserling H.L. et al. Safety and immunogenicity of heptavalent pneumococcal conjugated to CRM197 in United States infants. Pediatrics 1998; 101 (4, Pt 1): 604-611.Center K.J., Strauss A. Safety experience with heptavalent pneumococcal CRM197!conjugate vaccine (Prevenar) since vaccine introduction. Vaccine 2009; 27 (25-26): 3281-3284.Center K.J., Strauss A. Safety experience with heptavalent pneumococcal CRM197!conjugate vaccine (Prevenar) since vaccine introduction. Vaccine 2009; 27 (25-26): 3281-3284.Destefano F., Pfeifer D., Nohynek H. Safety profile of pneu mococcal conjugate vaccines: systematic review of pre and postlicensure data. Bull. Wld Hlth Org. 2008; 86 (5): 373-380.Destefano F., Pfeifer D., Nohynek H. Safety profile of pneu mococcal conjugate vaccines: systematic review of pre and postlicensure data. Bull. Wld Hlth Org. 2008; 86 (5): 373-380.Chevallier B., Vesikari T., Brzostek J. et al. Safety and reac togenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD!CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 2009; 28 (4, Suppl.): S109- S118.Chevallier B., Vesikari T., Brzostek J. et al. Safety and reac togenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD!CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 2009; 28 (4, Suppl.): S109- S118.Sinha A., Levine O., Knoll M.D. et al. Cost!effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007; 369 (9559): 389-396.Sinha A., Levine O., Knoll M.D. et al. Cost!effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007; 369 (9559): 389-396.Ongkasuwan J., Valdez T.A., Hulten K.G. et al. Pneumo coccal mastoiditis in children and the emergence of mul tidrugresistant serotype 19A isolates. Pediatrics 2008; 122 (1): 34-39.Ongkasuwan J., Valdez T.A., Hulten K.G. et al. Pneumo coccal mastoiditis in children and the emergence of mul tidrugresistant serotype 19A isolates. Pediatrics 2008; 122 (1): 34-39.Sampson J.S., Furlow Z., Whitney A.M. et al. Limited diver sity of Streptococcus pneumoniae psaA among pneumococ cal vaccine serotypes. Infect. and Immun. 1997; 65: 1967-1971.Sampson J.S., Furlow Z., Whitney A.M. et al. Limited diver sity of Streptococcus pneumoniae psaA among pneumococ cal vaccine serotypes. Infect. and Immun. 1997; 65: 1967-1971.Lock R.A., Paton J.C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae infection. Microb. Pathogen. 1988; 5: 461-467.Lock R.A., Paton J.C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae infection. Microb. Pathogen. 1988; 5: 461-467.Briles D.E., Hollingshead S.K., Swiatlo E. et al. PspA and PspC: Their potential for use as pneumococcal vaccines. Microb. Drug. Resist. 1997; 3: 401-408.Briles D.E., Hollingshead S.K., Swiatlo E. et al. PspA and PspC: Their potential for use as pneumococcal vaccines. Microb. Drug. Resist. 1997; 3: 401-408.McDaniel L.S., Sheffield J.S., Delucchi P. et al. PspA, a sur face protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect. Immun. 1991; 59: 222-228.McDaniel L.S., Sheffield J.S., Delucchi P. et al. PspA, a sur face protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect. Immun. 1991; 59: 222-228.Wu H.-Y., Nahm M.H., Guo Y. et al. Intranasal immuniza tion of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 1997; 175: 839-846.Wu H.-Y., Nahm M.H., Guo Y. et al. Intranasal immuniza tion of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 1997; 175: 839-846.Nayak A.R., Tinge S.A., Tart R.C. et al. A live recombinant virulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. and Immun. 1998; 66: 3744-3751.Nayak A.R., Tinge S.A., Tart R.C. et al. A live recombinant virulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. and Immun. 1998; 66: 3744-3751.McDaniel L.S., Loechel F., Benedict C. et al. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. Gene Ther. 1997; 4: 375-377.McDaniel L.S., Loechel F., Benedict C. et al. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. Gene Ther. 1997; 4: 375-377.
The authors declare that there are no conflicts of interest present.